Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 292-334-0 | CAS number: 90604-40-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
In the key study, no adverse effects were seen after dietary administration of Alcohols, C14-15-branched and linear for 90 days to rats Alcohols, C12-15-branched and linear (Ito et al., 1978). This is supported by a limited study in which no adverse effects were seen in the liver or testis after oral administration of Alcohols C12-15 branched and linear to male rats at 209 mg/kg bw/day for 14 days (Rhodes et al. 1984). A read-across from a reliable 13-week dietary study in rats using Hexanol reported a NOAEL of 1127 mg/kg bw/day and no adverse effects were noted at any of the dose levels administered during the study (Scientific Associates Inc. 1966).
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 3 548 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No repeated dose toxicity studies performed to international guidelines were available on Alcohols C12-15-branched and linear by any route, but one oral study with limitations has been reported.
The key study was performed using a protocol similar to OECD guideline 408 but prior to the introduction of GLP. The test material Alcohols, C14-15-branched and linear was administered to rats via the diet for 90 days at concentrations of 0, 0.2, 1 and 5% (providing average intakes of 169, 747 or 3548 mg/kg bw/day, respectively). The top and intermediate dose level (5 and 1%, respectively) had limited palatability and induced a considerable reduction in growth (>30% and approx. 15% reduction in body weight in high and mid dose males, respectively). Biochemistry showed increased liver enzyme activity (alkaline phosphatase and alanine aminotransferase) at the 1 and/or 5% level. It is considered that the increases in hepatic enzymes are not adverse as there was no associated pathology. The increase in relative weights of a number of organs is attributable to the reduced body weight due to lower food consumption as a result of lack of palatability. No treatment-related microscopic changes were observed, including both the testis and ovaries at this same dose level. Based on the effect on body weight a NOAEL was established at the 5% dietary incorporation level (approx. 3548 mg/kg/day) (Ito et al., 1978).
The Category hypothesis is that the long chain linear aliphatic alcohol family has at its centre an homologous series of increasing carbon chain length, which is associated with a consistency and predictability in the property data across the group, for the physicochemical, environmental and toxicological property data sets. In view of the structural and chemical similarities, it is considered that the results from a number of reliable repeated dose toxicity studies on single- or multiple-constituent alcohols with appropriate chain lengths can be read across to Alcohols C12-15 branched and linear.
For Hexanol, oral NOAELs were 1127 and 1243 mg/kg bw/day (the highest doses tested) in male and female rats respectively in a 90-day repeated dose toxicity test in which a somewhat limited range of endpoints was evaluated (Scientific Associates 1966a).
For Hexadecanol, oral NOAELs were > 4257 and > 4567 mg/kg bw/day in male and female rats respectively in a 90-day repeated dose toxicity test in which a somewhat limited range of endpoints was evaluated (Scientific Associates 1966a). Using a protocol similar to OECD guideline 407, a GLP study, in which male and female rats were administered Hexadecanol by oral gavage on 5 days/week for 28 days, established an NOAEL of >1000 mg/kg bw/day, the highest dose tested (Henkel 1985a).
An oral NOAEL of 2000 mg/kg bw/day (the highest dose tested) was established in rats for Dodecanol, in a combined repeat dose and reproductive/developmental toxicity screening test performed to draft OECD guideline 422 and to GLP (Hansen 1992a). No maternal toxicity was seen in rats after oral gavage dosing with Alcohols C7-11 branched and linear at up to 1440 mg/kg bw/day on days 6 to 15 of gestation and this top dose was therefore the NOAEL (Hellwig & Jackh 1997).
For Alcohols, C12 -16, data are available from a research publication in which the test material was dissolved in polyethylene glycol 300 and administered to male rats by oral gavage at 209 mg/kg bw/day for 14 days. There were no adverse effects on the small number of endpoints measured (liver and testis weight and histopathological examination of the liver). An NOAEL of 209 mg/kg bw/day was identified from this limited study (Rhodes et al. 1984).
In a limited study, conducted prior to the introduction of GLP, Alcohols C16-18 and C18 unsatd. was administered to male and female at a single dose level of 840 mg/kg bw/day by oral gavage and no toxicity was reported (Henkel 1973).
No repeated dose toxicity studies were available on any of the long chain linear aliphatic alcohol family by the dermal route.
No reliable guideline repeated dose toxicity studies were available on any of the relevant members of the long chain linear aliphatic alcohol family by the inhalation route.
Discussion of trends in the Category of C6-24 linear and essentially-linear aliphatic alcohols: In summary, the sub-category of the linear LCAAs is of a low order of toxicity upon repeated exposure. The LCAAs at lower end of this group caused local irritation at the site of first contact and induced signs ofdepression and respiratory effects when administered at very high dose levels and only as a bolus dose (C6, C8 alcohol) in the dog (C6 alcohol) and the rat (C8 alcohol). Other routes of exposure induced no apparent neurotoxicity either centrally or peripherally. Intermediate (>C8 to C12) and higher (>C12) linear LCAAs are non-irritant at the site of first contact and are without a neurotoxic potential. At high dose levels some of the higher LCAAs showed changes in clinical chemistry and liver weight but without further evidence of systemic toxicity; this finding may be indicative of mild, sub-clinical effects in the liver. There are no species differences observed for this sub-category, based on a comparison of the results of parallel studies in the rat and the dog. In summary, the data for the essentially linear LCAAs, including the data from supporting substances, indicate a low order of toxicity upon repeated exposure. A consistent finding for this group is the effect on the liver: mild organ weight increases and/or slight clinical chemical changes but without evidence of significant histopathological effects. The clinical chemistry changes were generally of a slight grade but showed some inconsistencies, some of which relating to decreases in transferase activity, a change not normally associated with adverse hepatic effects. The (small) degree of the liver weight increases, the pattern of the clinical chemical changes and the absence of markers support the conclusion that this sub-category of LCAAs lacks a potential for the induction of peroxisomal proliferation. There is evidence of irritation at the first site of contact for the lower members of this group. Conclusion: The repeat dose toxicity of the category of LCAAs with chain lengths ranging from C6 to C22 indicates a low order of toxicity upon repeated exposure. Typical NOAEL’s recorded for this category range between approx. 200 mg/kg/day to 1000 mg/kg/day in the rat upon sub-chronic administration via the diet. No adverse systemic effects have been seen in reliable studies with members of the Category of C6-24 Alcohols, therefore the NOAELs represent the highest dose tested. At the lower end, members of this category induce local irritation at the site of first contact. Other notable findings observed for several members within this group suggest mild changes consistent with low-grade liver effects with the changes in essentially linear LCAAs being slightly more pronounced than in linear alcohols. Typical findings include: slightly increased liver weight, in some cases accompanied by clinical chemical changes but generally without concurrent histopathological effects. Special studies demonstrated that this category does not have a potential for peroxisome proliferation. A potential for depression as observed for short chain aliphatic alcohols (C1 to C4; not included in this category) was also identified for 1-hexanol and 1-octanol, however this effect was only expressed upon repeated administration of a bolus dose; effects were absent upon inhalation or dietary administration. Similarly, 1-hexanol and 1-octanol induced respiratory distress upon repeated administration of a bolus dose. LCAAs do not have a potential for peripheral neuropathy. Furthermore, the data from the substances supporting this category (i.e. isoamyl alcohol), demonstrate that the toxicological profile of the repeated dose toxicity of 100% branched alcohols is qualitatively similar to that of the corresponding essentially linear alcohols. Chronic and sub-chronic toxicity studies have shown that LCAAs are of low toxicity. Furthermore, combined repeated-dose studies with developmental endpoints, as well as reproductive and developmental studies showed no effects at the highest dose tested. Where data gaps exist, the gap is filled by read-across from reliable evidence within the C6-24 Alcohols Category, where possible using interpolation between at least two reliable studies using higher and lower carbon number test substances. Repeated dose toxicity data for the Category
Linear Alcohols |
Essentially Linear Alcohols |
|||||||||||
|
CAS |
CHEMICAL NAME |
Species/ Study type/ Duration1 |
Route |
NOAEL
(Ref) |
Rel. |
CAS |
CHEMICAL NAME |
Species/ Study type/ Duration1 |
Route
|
NOAEL (Ref) |
Rel. |
C5 |
|
|
|
|
|
|
123-51-3 |
Isoamyl alcohol (supporting) |
Rat 17 wk |
Gavage |
500 mg/kg |
2 |
C6 |
111-27-3 |
Hexan-1-ol |
Dog 13 wk |
Diet |
370 mg/kg |
2
|
|
|
|
|
|
|
Rat 13 wk |
Diet |
1127 mg/kg (Sc.Assoc.’66) |
2
|
|||||||||
Rat 3 wk |
Diet |
1000 mg/kg bw/day (Moody, 1978-1982) |
2 |
|||||||||
Rat subchronic 30 wk |
Intraperit oneal |
No peripheral neuropathy (Perbelliniet al., 1978) |
2 |
|||||||||
C7 |
|
|
|
|
|
|
|
Alcohols, C7-9 |
Rat 1-wk |
Gavage |
4175 mg/kg 128 mg/kg |
2 |
Rat 1 wk |
Gavage |
128 mg/kg(Rhodes, 1984) |
2 |
|||||||||
C8 |
60435-70-3 |
2-methylheptan-1-ol |
|
|
|
|
|
|
|
|
|
|
C8 |
111-87-5 |
Octan-1-ol |
Rat |
gavage |
130 mg/kg (Hellwig, 1997) No systemic toxicity expected based on read across of a dermal study on Fatty Alcohol Blend of which octan-1-ol is a constituent, and on read-across from an oral study on hexan-1-ol. No adverse systemic effects were observed at the highest dose in either study. |
2 |
|
|
|
|
|
|
C8 |
|
|
|
|
|
|
|
Fatty Alcohol Blend |
rat 90 day |
dermal |
1000 mg/kg bw/day (WIL, 1995) |
2 |
C9 |
143-08-8 |
Nonan-1-ol |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
|
68515-81-1 |
Nonan-1-ol, branched and linear |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
|
C9 |
|
|
|
|
|
|
|
Alcohols, C9-11- branched and linear |
Rat 9-day
Rat 2 wk |
Inhalation
Gavage |
>0.158 mg/L.(Darmer, 1982) <4150 mg/kg(Brown, 1970) |
2
2 |
C10 |
112-30-1 |
Decan-1-ol |
|
|
No systemic toxicity expected based on read across of a dermal study on Fatty Alcohol Blend of which decan-1-ol is a constituent, and on read-across from an oral study on hexan-1-ol. No adverse systemic effects were observed at the highest dose in either study. |
|
90342-32-8 |
Decan-1-ol, branched and linear |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
|
C11 |
112-42-5 |
Undecan-1-ol |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
2 |
128973-77-3 |
Undecan-1-ol, branched and linear Reaction mass of 2-methyldecan-1-ol and 2-propyloctan-1-ol and 2-ethylnonan-1-ol and 2-butylheptan-1-ol |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
|
C12 |
112-53-8 |
Dodecan-1-ol |
Rat 5wk |
Diet |
2000 mg/kg (Hansen,1992a) |
2 |
75782-86-4 |
Alcohols, C12-13 |
Rat 4wk
|
Gavage
|
300 mg/kg; (Sasol, 1999 |
1 |
C12 |
|
|
|
|
|
|
740817-83-8 |
Alcohols, C12-13-branched and linear |
Rat 4wk (read-across)
|
Gavage
|
300 mg/kg; (Sasol, 1999 |
1 |
C12 |
|
|
|
|
|
|
90604-40-3 |
Alcohols, C12-15-branched and linear |
Rat 2 wk |
Gavage
|
209 mg/kg(Rhodes, 1984) |
2 |
C13 |
112-70-9 |
1-Tridecan-1-ol (supporting) |
Rat 2 wk |
Gavage |
184 mg/kg (Rhodes, 1984) |
2 |
90583-91-8 |
Tridecan-1-ol, branched and linear (supporting) |
|
|
Low systemic toxicity expected |
2 |
C14 |
112-72-1 |
Tetradecan-1-ol |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
2 |
75782-87-5 |
Alcohols, C14-15 |
Rat 90 day |
Diet |
167 mg/kg; |
2 |
C14 |
|
|
|
|
|
|
|
Alcohols, C14-15-branched and linear |
Rat 90 day (read-across) |
Diet |
167 mg/kg; |
2 |
C15 |
629-76-5 |
Pentadecan-1-ol |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
2 |
90480-71-0
|
Pentadecan-1-ol, branched and linear |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
2 |
C16 |
36653-82-4 |
Hexadecan-1-ol |
Rat 4 wk
Dog 13 wk
Rat 13 wk |
Diet
Diet
Diet |
>1000 mg/kg (Henkel, 1985a) >1054 mg/kg (Sc.Assoc, 1966b) >4257 mg/kg |
2
2 2 |
|
Alcohols, C16-17; Alcohols, C16-17 -branched and linear; Alcohols, C16-17-monobranched |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
|
C18 |
143-28-2 |
9-Octadecen-1-ol, (9Z)- |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
2 |
|
|
|
|
|
|
C18 |
112-92-5 |
Octadecan-1-ol |
Rat 4 wk
Rat 5 wk |
Gavage
Diet |
>1000 mg/kg (Henkel, 1986a) 2000 mg/kg (Hansen, 1992b) |
1
2 |
|
|
|
|
|
|
C20 |
629-96-9 |
Icosanan-1-ol |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
2 |
|
|
|
|
|
|
C22 |
661-19-8 |
Docosan-1-ol |
Rat 26 wk
Dog 26 wk |
Gavage
Gavage |
1000 mg/kg (Iglesias,2002a) 2000 mg/kg (Iglesias,2002a) |
1
1 |
|
|
|
|
|
|
C24 |
506-51-4 |
Tetracosan-1-ol |
|
|
No systemic toxicity expected based on data for category indicating no adverse systemic effects at highest dose tested. |
|
|
|
|
|
|
|
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The selected study was conducted according to a protocol similar to an appropriate OECD guideline using structural analogue Alcohols, C14-15, branched and linear.
Justification for classification or non-classification
Based on the available data, Alcohols C12-15 branched and linear would not be classified for specific target organ toxicity-repeated exposure under Regulation (EC) No. 1272/2008 (CLP) since no adverse effects occurred at <100 mg/kg bw/day, since no adverse effects occurred at <50 mg/kg bw/day. Tests on similar substances included in this category are also supportive of these results, which do not warrant classification under GHS criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
